Lantern Pharma Inc.

US$0.57As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:LTRNHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (38.66%)
Div yield —
ROE (400.92%)
Biotechnology
Beta (5Y) 2.46
PE TTM —
TSR TTM (85.84%)
Mkt cap US$7.260M
ROIC (203.72%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.704
24.03%
(16.88%)
Hold 7|1|8|9|1
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.01
0.01
0.01
0.01
20.56%
9.70%
9.24%
22.28%
Revenue$M
0.731
0.760
0.789
0.766
19.04%
17.34%
15.85%
8.94%
Peers (US$7.260M)
Cap (US$)
PE
7.291M
—
Capital
TTM
5Y
10Y
Leveragex
1.358
0.244
0.204
EBIT/Intx
21.44
0.408
0.319
Own earn%
(142.71)
(41.76)
(40.06)
Sh yield%
54.91
33.74
33.80
Owners
Insiders/Inst%
0.65
36.20
Short interest%
1.24
SBC / revenue%
2.45
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
24
Op margin range%
7–12
$1 testx
−4.5
Incr. ROIC%
4